10.08.2020 - Starting 1 July 2020, Roche Diagnostics Germany cooperates with the Munich-based medtech company inveox. The aim of the collaboration is to jointly advance the digitization of histopathology labs to increase the safety and reliability of diagnostic findings and to make workflows even more efficient.
The processing and analysis of tissue samples in the histopathology laboratory can be subject to irregularities during the work process. When tissue samples are labeled or marked manually, there is a risk of mix-ups, which can in the worst case result in an inaccurate diagnosis and lead to patients not receiving the right therapy or not being treated at all.
The use of digital workflow solutions is intended to increase patient safety. So far, the use of the Roche Vantage Workflow Solution required a connection to the respective Laboratory Information System (LIS). However, as there are histopathology laboratories where this connection is not implemented, Roche Diagnostics Germany and inveox have now created the possibility to make this workflow solution available to all customers by offering a jointly developed alternative to the LIS connection. For this purpose, inveox has implemented a sample entry module, which allows the Roche workflow solution to be used independently of the LIS used by the customer.
Christian Paetzke, Managing Director of Roche Diagnostics Germany, says: “Thanks to a successful collaboration with inveox, our digital workflow solution is now accessible to all customers and provides the opportunity to further increase the quality of diagnostics.” Dominik Sievert, Founder and CEO of inveox, welcomes the cooperation as a continuation of a productive relationship that has built up over the past several years: “As a young, ambitious medtech company, we highly appreciate having Roche on our side as a strong cooperation partner. I am looking forward to working with Roche to advance digital diagnostics in histopathology.”
Patient safety and efficiency in the lab
The Vantage Workflow Solution provides end-to-end tracking of patient samples, multiple quality management features, and extensive software-based capabilities for real-time analysis of laboratory processes. This reduces the risk of sample mix-ups while increasing laboratory efficiency and quality. The solution by inveox also minimizes the risk of sample mix-ups, improves patient safety and promotes integrated cancer diagnostics. It consists of a coded, intelligent sample container, a device to automate sample entry and a software enabling data transfer between the treating physician and the pathology lab.
Roche employs around 16,700 people in Germany in the fields of pharmaceuticals and diagnostics. The company is represented at three major sites in Grenzach-Wyhlen (Roche Pharma AG), Mannheim (Roche Diagnostics GmbH, Roche Diagnostics Deutschland GmbH, Roche Diabetes Care GmbH and Roche Diabetes Care Deutschland GmbH) and Penzberg (Biotechnologie-Kompetenzzentrum, Roche Diagnostics GmbH). The main focus of the company’s activities covers the entire value-added chain of the two business areas of pharmaceuticals and diagnostics: from research and development to production, logistics, marketing and sales, with each location also performing global tasks in addition to its German business. Roche clearly commits to its German sites and has invested over 2.7 billion euros in these over the past five years. Further information on Roche in Germany can be found at www.roche.de/en
About inveox GmbH
inveox GmbH, founded in Munich in 2017, develops systems to digitize, automate and connect histopathology laboratories. The aim is to increase the safety and reliability of cancer diagnoses, while at the same time improving the efficiency and profitability of laboratories and tapping the potential for personalized diagnostics based on Big Data and Artificial Intelligence.
Since its founding, inveox has won numerous awards and became part of several accelerators of renowned companies, such as “Digital Health” (Roche Diagnostics / Plug&Play), the Texas Medical Center Accelerator in Houston (Texas) and the German Accelerator Life Sciences in Boston (Massachusetts). The young company made it onto the Forbes list of the “most promising startups” and was a finalist in the German Innovation Prize. At the end of 2018, inveox opened a subsidiary in Krakow (Poland), followed by a subsidiary in Houston (Texas) in spring 2020. Since 2019, inveox has been a member of the World Economic Forum. It currently has a combined work force of 89 colleagues in all offices.
All mentioned brand names are protected by law.
For further information, please contact:
Head of Marketing & Communications
85748 Garching bei München
Tel.: +49 (0) 157 92348482
Roche Diagnostics Deutschland GmbH
Head of Communications
Sandhofer Straße 116